Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGuangzhou, China, December 24, 2024 - Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovative therapies and a pipeline of biosesimilars, today announced the companyhas partnered with Tabuk PharmaceuticalManufacturing Company (a fully-ownedsub...
GUANGZHOU, China - Bio-Thera Solutions, a commercial-stage biopharmaceutical companydeveloping innovative therapies and biosesimilars today announced an expansion oftheir partnership with SteinCares today with the addition of a third biosesimilarto the partnership. Under the agreement,SteinCares will ha...
Guangzhou, China/Budapest, Hungary– # October 9,2024 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosesimilars, and Gedeon Richter (“Richter”) announce today they have reached anexclusive comme...
